Croda International Plc (LON:CRDA)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 3.95B +6.1% |
| Revenue (ttm) | 1.70B +4.4% |
| Net Income | 62.00M -60.9% |
| EPS | 0.44 -60.9% |
| Shares Out | 139.35M |
| PE Ratio | 63.90 |
| Forward PE | 17.91 |
| Dividend | 1.11 (3.82%) |
| Ex-Dividend Date | Apr 9, 2026 |
| Volume | 486,509 |
| Average Volume | 395,948 |
| Open | 2,898.00 |
| Previous Close | 2,905.00 |
| Day's Range | 2,837.00 - 2,903.60 |
| 52-Week Range | 2,426.77 - 3,312.00 |
| Beta | 0.93 |
| RSI | 43.89 |
| Earnings Date | Jul 28, 2026 |
About Croda International
Croda International Plc engages in the consumer care, life science, and industrial specialty businesses in Europe, the Middle East, Africa, North America, Asia, and Latin America. The company offers consumer care products across beauty care, beauty actives, and home care products, as well as fragrances and flavours. It also provides biologics drug delivery, crop protection, and seed coating systems and enhancement technologies to improve germination. In addition, the company offers industrial specialties, including phase change materials; surfa... [Read more]
Financial Performance
In 2025, Croda International's revenue was 1.70 billion, an increase of 4.38% compared to the previous year's 1.63 billion. Earnings were 62.00 million, a decrease of -60.88%.
Financial StatementsNews
Croda International Earnings Call Transcript: Q1 2026
Q1 2026 sales rose 1% at constant currency, with Consumer Care up and Life Sciences down. No material impact from Middle East conflict; full-year outlook unchanged, supported by strong order book, ongoing transformation, and price increases to offset inflation.
Croda International Earnings Call Transcript: H2 2025
Sales rose 7% in constant currency with strong growth in patented ingredients and Consumer Care. Transformation initiatives are driving margin recovery, with a target of over 20% operating margin by 2028 and free cash flow conversion above 12%.
Croda International Earnings Call Transcript: Q3 2025
Sales rose 6.5% in constant currency, led by innovation in Beauty Actives and F&F, with Crop recovering. Full-year guidance is unchanged amid market uncertainty, with cost savings and margin recovery on track. Q4 is expected to be seasonally lower.
Croda International shares jump after Standard Industries unit discloses stake
Shares of Croda International Plc surged 4.7% on Thursday, marking the British chemicals supplier's strongest daily gain since April 23. The rally came after a filing revealed that Standard Latitude M...
Croda International Earnings Call Transcript: H1 2025
First half results showed 7% sales growth and 12% profit growth, driven by strong volumes and cost savings, despite price pressures and macro uncertainty. The transformation program targets £100 million in annualized savings by 2027, with full-year guidance unchanged.
Croda International Transcript: Trading Update
Sales grew 8% (9% at constant currency) in Q1, led by strong volumes across all businesses and improved asset utilization. Tariff surcharges are being applied, with no evidence of pre-buying, and full-year guidance is unchanged amid a stable margin and ongoing cost savings.
Croda International Earnings Call Transcript: H2 2024
Sales declined 4% but profits met guidance due to cost control, with strong free cash flow and a modest dividend increase. Consumer Care and Life Sciences are set for growth in 2025, supported by operational efficiencies and a focus on local/regional customers.
Croda International Earnings Call Transcript: H1 2024
First half 2024 saw sequential sales and margin improvement, led by Consumer Care and innovation, despite a 7% revenue decline year-over-year. Free cash flow surged 69%, and the outlook remains positive for most segments, though Crop Protection and Consumer Health are still weak.
Croda International Transcript: Trading Update
Partnership agreement between Croda and AAHI to drive innovation in vaccine development
SEATTLE--(BUSINESS WIRE)--Croda International Plc (Croda) and The Access to Advanced Health Institute (AAHI) are pleased to announce today the signing of a partnership agreement around innovation and ...
Croda International Earnings Call Transcript: H2 2023
Croda International Transcript: Trading Update
Croda: Navigating Challenges and Driving Growth
In the first half of 2023, Croda International PLC ( LSE:CRDA , Financial), a leading global specialty chemicals company, demonstrated its ability to adapt to challenging market conditions while conti...
Croda International Earnings Call Transcript: H1 2023
Croda International Transcript: Trading Update
Croda International Has Growth and Value Potential
Founded in 1925, Croda International PLC ( LSE:CRDA , Financial) ( COIHF , Financial) produces ingredients for various industries, including consumer cosmetics, pharmaceuticals and agriculture. The co...